Methoxsalen solution

Drug Profile

Methoxsalen solution

Alternative Names: UVADEX

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator Therakos
  • Developer Mallinckrodt Inc.; Therakos
  • Class Antipsoriatics; Psoralens
  • Mechanism of Action DNA cross linking agents; Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cutaneous T cell lymphoma
  • Phase III Graft-versus-host disease

Most Recent Events

  • 01 Sep 2015 Phase-III clinical trials in Graft-versus-host disease (In adolescents, In adults, In children, In infants) in USA (Extracorporeal) (NCT02524847)
  • 01 Sep 2015 Phase-III clinical trials in Graft-versus-host disease (In adolescents, In adults, In infants, In children) in Hungary (Extracorporeal) (NCT02524847)
  • 01 Sep 2015 Phase-III clinical trials in Graft-versus-host disease (In adolescents, In adults, In infants, In children) in United Kingdom (Extracorporeal) (NCT02524847)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top